Treatment of venous thromboembolism: duration and new options.
Huisman
Menno V
MV
Leiden University Medical Center, Leiden, Nederland.
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines; D017326:Clinical Trials, Phase III as Topic; D015195:Drug Design; D065427:Factor Xa Inhibitors; D005500:Follow-Up Studies; D000077425:Fondaparinux; D006801:Humans; D011134:Polysaccharides / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013923:Thromboembolism / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D019851:Thrombophilia / Q000150:complications; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D065427:Factor Xa Inhibitors; D011134:Polysaccharides; D014812:Vitamin K; C426686:ximelagatran; D000077425:Fondaparinux